RBC: "How LLY Could Blaze a Trail and BIIB Could Pull AHEAD In The Large, Overlooked Pre-Sx AD Mkt"
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $213.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "We've ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
